CoChat

Use of Immune Checkpoint Inhibitors in the Treatment of Patients With Cancer and Preexisting Autoimmune Disease

Abdel-Wahab, Noha, Shah, Mohsin, Lopez-Olivo, Maria A., Suarez-Almazor, Maria E. · 2018 · Annals of Internal Medicine
Cited by 63

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Abstract

Letters17 July 2018Use of Immune Checkpoint Inhibitors in the Treatment of Patients With Cancer and Preexisting Autoimmune DiseaseNoha Abdel-Wahab, MD, PhD, Mohsin Shah, MD, Maria A. Lopez-Olivo, MD, PhD, and Maria E. Suarez-Almazor, MD, PhDNoha Abdel-Wahab, MD, PhDUniversity of Texas MD Anderson Cancer Center, Houston, Texas (N.A., M.S., M.A.L., M.E.S.)Search for more papers by this author, Mohsin Shah, MDUniversity of Texas MD Anderson Cancer Center, Houston, Texas (N.A., M.S., M.A.L., M.E.S.)Search for more papers by this author, Maria A. Lopez-Olivo, MD, PhDUniversity of Texas MD Anderson Cancer Center, Houston, Texas (N.A., M.S., M.A.L., M.E.S.)Search for more papers by this author, and Maria E. Suarez-Almazor, MD, PhDUniversity of Texas MD Anderson Cancer Center, Houston, Texas (N.A., M.S., M.A.L., M.E.S.)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/L18-0209 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail IN RESPONSE:Because our article was a systematic review of reported cases in the literature, we were limited by the quality of information available in the original articles. Insufficient reporting of certain data was acknowledged. As such, we did not report information on the extent of tumor mass at the time of adverse events. We have included only reports describing patients with an established diagnosis of autoimmune disease before initiation of checkpoint inhibitor (CPI) therapy for concomitant cancer. We based our determination on the reports of the authors of the original articles, and most of these autoimmune diseases—such as psoriasis, ...References1. Fam AG. Paraneoplastic rheumatic syndromes. Baillieres Best Pract Res Clin Rheumatol. 2000;14:515-33. [PMID: 10985984] CrossrefMedlineGoogle Scholar2. Manger B, Schett G. Paraneoplastic syndromes in rheumatology. Nat Rev Rheumatol. 2014;10:662-70. [PMID: 25136782] doi:10.1038/nrrheum.2014.138 CrossrefMedlineGoogle Scholar3. Weber JS, Hodi FS, Wolchok JD, Topalian SL, Schadendorf D, Larkin J, et al. Safety profile of nivolumab monotherapy: a pooled analysis of patients with advanced melanoma. J Clin Oncol. 2017;35:785-92. [PMID: 28068177] doi:10.1200/JCO.2015.66.1389 CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAffiliations: University of Texas MD Anderson Cancer Center, Houston, Texas (N.A., M.S., M.A.L., M.E.S.)Disclosures: Disclosures can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M17-2073. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoUse of Immune Checkpoint Inhibitors in the Treatment of Patients With Cancer and Preexisting Autoimmune Disease Noha Abdel-Wahab , Mohsin Shah , Maria A. Lopez-Olivo , and Maria E. Suarez-Almazor Use of Immune Checkpoint Inhibitors in the Treatment of Patients With Cancer and Preexisting Autoimmune Disease Yasuo Oshima , Noboru Hagino , Masumi Hara , and Takashi Ohfuji Metrics Cited byManagement of Cancer-Associated MyositisTreatment of rheumatic adverse events of cancer immunotherapyRespiratory ComplicationsBone Marrow–Liver–Thymus ( BLT ) Humanized Mice as a Tool to Assess Checkpoint Inhibitor Adverse EventsImmune Checkpoint Blockade and Skin Toxicity PathogenesisPulmonary Complications of Lung Cancer TherapiesRheumatic Manifestations and Diseases From Immune Checkpoint Inhibitors in Cancer ImmunotherapyReal-World Clinical and Economic Outcomes in Selected Immune-Related Adverse Events Among Patients with Cancer Receiving Immune Checkpoint InhibitorsImmune Checkpoint Inhibitors and Kidney Toxicity: Advances in Diagnosis and ManagementPyroptosis-Related Gene Signatures Can Robustly Diagnose Skin Cutaneous Melanoma and Predict the PrognosisCheckpoint inhibitor therapy for metastatic triple-negative breast cancerSafety and Efficacy of Checkpoint Inhibition in Patients With Melanoma and Preexisting Autoimmune Disease A Cohort StudyMonique K. van der Kooij, MD, Karijn P.M. Suijkerbuijk, MD, PhD, Maureen J.B. Aarts, MD, PhD, Franchette W.P.J. van den Berkmortel, MD, PhD, Christian U. Blank, MD, PhD, Marye J. Boers-Sonderen, MD, PhD, Jesper van Breeschoten, MSc, Alfonsus J.M. van den Eertwegh, MD, PhD, Jan Willem B. de Groot, MD, PhD, John B.A.G. Haanen, MD, PhD, Geke A.P. Hospers, MD, PhD, Djura Piersma, MD, PhD, Rozemarijn S. van Rijn, MD, PhD, Albert J. ten Tije, MD, PhD, Astrid A.M. van der Veldt, MD, PhD, Gerard Vreugdenhil, MD, PhD, Michiel C.T. van Zeijl, MD, Michel W.J.M Wouters, MD, PhD, Olaf M. Dekkers, MD, PhD, and Ellen Kapiteijn, MD, PhDNeurological Complications of Targeted Therapies and Immunotherapies for CancerInternational Consensus Guidance for Management of Myasthenia GravisMarked improvement of oral intake with nivolumab monotherapy in a patient with microsatellite instability‐high gastric cancer with insufficient oral intakeSarcoidosisCheckpoint inhibitors: In

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.7326/l18-0209

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

Metadata

Authors
Abdel-Wahab, N., Shah, M., Lopez-Olivo, M. A., & Suarez-Almazor, M. E.
Venue
Annals of Internal Medicine
Published
2018-07-17
Volume
169
Issue
2
Pages
133-134
ISSN
  • 0003-4819 (ISSN-L)
  • 1539-3704
OpenAlex
W2883350403
Cited by
63
References
1
FWCI
3.12
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.